FLT3 and acute myeloid leukemia: Furthermore, in an Italian compassionate use program that recruited patients aged 52–79 years with secondary AML, three of five patients with a FLT3-ITD mutation achieved CR/CRi with CPX-351; the 12-month OS was 60% (16).